The effect of oat bran consumption on gestational diabetes: a randomized controlled clinical trial.
Fasting blood sugar
Oat bran
Two-hour post-prandial (2hpp) glucose
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
01
12
2020
accepted:
04
04
2021
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Gestational diabetes is the most common medical complication in pregnancy, and it has many side effects for the mother and the fetus. The aim of this study was to evaluate the effect of oat bran consumption on gestational diabetes. This study is a randomized clinical trial that was performed on 112 women with gestational diabetes treated with diet. Participants were randomly divided into two groups of 56. Participants in both groups were given a diet for gestational diabetes. In addition to the diet, the intervention group received 30 g of oat bran daily for 4 weeks at lunch and dinner. Tests of fasting blood glucose and two-hour postprandial (2hpp) glucose were taken from both groups: before the intervention, and 2 and 4 weeks after the start of the intervention. Data analysis was performed using SPSS statistical software (version 22) using independent t-test, as well as Chi-square and Mann-Whitney tests. P values less than 0.05 were considered statistically significant. There was no statistically significant difference between the two groups in terms of mean blood glucose before the intervention, while 2 and 4 weeks after the intervention, mean fasting blood glucose and two-hour postprandial (2hpp) glucose decreased significantly in the intervention group compared with the control group (P < 0.001). Based on the results of this study, the addition of oat bran to the standard diet for pregnant women with gestational diabetes reduced fasting blood glucose and two-hour postprandial (2hpp) glucose. More detailed studies with higher sample sizes are recommended to prove the effectiveness of this valuable dietary supplement. IRCT registration number: IRCT20191220045828N1 . Registration date: 2020-04-18. Registered while recruiting.
Sections du résumé
BACKGROUND
BACKGROUND
Gestational diabetes is the most common medical complication in pregnancy, and it has many side effects for the mother and the fetus. The aim of this study was to evaluate the effect of oat bran consumption on gestational diabetes.
METHODS
METHODS
This study is a randomized clinical trial that was performed on 112 women with gestational diabetes treated with diet. Participants were randomly divided into two groups of 56. Participants in both groups were given a diet for gestational diabetes. In addition to the diet, the intervention group received 30 g of oat bran daily for 4 weeks at lunch and dinner. Tests of fasting blood glucose and two-hour postprandial (2hpp) glucose were taken from both groups: before the intervention, and 2 and 4 weeks after the start of the intervention. Data analysis was performed using SPSS statistical software (version 22) using independent t-test, as well as Chi-square and Mann-Whitney tests. P values less than 0.05 were considered statistically significant.
RESULTS
RESULTS
There was no statistically significant difference between the two groups in terms of mean blood glucose before the intervention, while 2 and 4 weeks after the intervention, mean fasting blood glucose and two-hour postprandial (2hpp) glucose decreased significantly in the intervention group compared with the control group (P < 0.001).
CONCLUSION
CONCLUSIONS
Based on the results of this study, the addition of oat bran to the standard diet for pregnant women with gestational diabetes reduced fasting blood glucose and two-hour postprandial (2hpp) glucose. More detailed studies with higher sample sizes are recommended to prove the effectiveness of this valuable dietary supplement.
TRIAL REGISTRATION
BACKGROUND
IRCT registration number: IRCT20191220045828N1 . Registration date: 2020-04-18. Registered while recruiting.
Identifiants
pubmed: 33849494
doi: 10.1186/s12902-021-00731-8
pii: 10.1186/s12902-021-00731-8
pmc: PMC8045255
doi:
Substances chimiques
Blood Glucose
0
Dietary Fiber
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Subventions
Organisme : Ahvaz Jundishapur University of Medical Sciences
ID : RHPRC-9825
Références
Ann Epidemiol. 2013 Jun;23(6):321-7
pubmed: 23608304
Diabetes Care. 2009 Oct;32(10):1823-5
pubmed: 19628814
Vasc Health Risk Manag. 2008;4(6):1265-72
pubmed: 19337540
Phytomedicine. 1995 Oct;2(2):137-89
pubmed: 23196156
J Nutr Metab. 2012;2012:851362
pubmed: 22187640
Arch Gynecol Obstet. 2016 May;293(5):959-66
pubmed: 26825733
Eur J Endocrinol. 2016 Feb;174(2):R43-51
pubmed: 26431552
Can J Diabetes. 2013 Apr;37 Suppl 1:S168-83
pubmed: 24070943
Taiwan J Obstet Gynecol. 2007 Sep;46(3):236-41
pubmed: 17962102
J Am Diet Assoc. 1996 Dec;96(12):1254-61
pubmed: 8948386
N Engl J Med. 2000 May 11;342(19):1392-8
pubmed: 10805824
Int J Cancer. 2006 Nov 15;119(10):2279-86
pubmed: 16921499
J Am Coll Nutr. 2013;32(4):272-9
pubmed: 24024772
Crit Rev Food Sci Nutr. 1994;34(5-6):499-511
pubmed: 7811380
Endocrine. 2009 Oct;36(2):268-74
pubmed: 19728183
Br J Nutr. 2014 Aug 14;112(3):457-66
pubmed: 24787712
Diabetes Care. 2007 Jul;30 Suppl 2:S251-60
pubmed: 17596481
Eur J Clin Nutr. 2002 Jul;56(7):622-8
pubmed: 12080401
Diabetes Res Clin Pract. 2017 Jul;129:173-181
pubmed: 28531829
Indian J Endocrinol Metab. 2013 Jul;17(4):689-92
pubmed: 23961487
Diabet Med. 2013 Nov;30(11):1314-23
pubmed: 23668675
Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):255-61
pubmed: 16054549
Nutrients. 2016 Aug 26;8(9):
pubmed: 27571099
World J Diabetes. 2015 Mar 15;6(2):284-95
pubmed: 25789109
J Obstet Gynecol Neonatal Nurs. 2011 Sep-Oct;40(5):603-14; quiz 614-6
pubmed: 22273418